Ir para o conteúdo principal

Gilead Sciences (NASDAQ: GILD) — Perfil da empresa, notícias e dados financeiros

Logo de Gilead Sciences
GILD Gilead Sciences
A medical doctors busy on their work in the laboratory.
Perfil da empresa

Gilead Sciences

Gilead Sciences is an American biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company's primary therapeutic focus areas include virology, oncology, and inflammation. Its product portfolio features antiviral therapies for the treatment and prevention of human immunodeficiency virus (HIV), viral hepatitis B and C, and COVID-19, alongside targeted cell therapies and oncology treatments for complex cancers. Headquartered in Foster City, California, Gilead operates clinical research and commercial facilities globally, advancing research programs to improve patient care and expand treatment access across international markets.

Resumo

Public USParticipação acionária
1987Ano de fundação
~17,000Funcionários
Foster City, United StatesSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Gilead Sciences

  • HIV Antiretroviral Therapies: Portfolio of single-tablet and combination antiviral regimens including Biktarvy, Descovy, and Genvoya. These therapies provide complete treatment and pre-exposure prophylaxis for millions of individuals living with or at risk of human immunodeficiency virus globally.
  • COVID-19 Antiviral Treatments: Intravenous nucleotide analog treatments, primarily Veklury (remdesivir), administered to pediatric and adult patients. Used across global hospital systems and outpatient facilities for early and severe viral infection management.
  • Viral Hepatitis Medicines: Direct-acting antiviral drug formulations including Epclusa, Harvoni, Sovaldi, and Vemlidy. These oral regimens target chronic hepatitis B and C viral infections to prevent liver damage, cirrhosis, and hepatic carcinoma.
  • Oncology and Antibody-Drug Conjugates: Target-directed biopharmaceutical therapies led by Trodelvy (sacituzumab govitecan-hziy). Designed to treat unresectable locally advanced or metastatic triple-negative breast cancer, HR-positive/HER2-negative breast cancer, and metastatic urothelial carcinomas.
  • Chimeric Antigen Receptor T-Cell Therapies: Autologous cell therapy manufacturing and treatment platforms including Yescarta and Tecartus. Engineered to target CD19 receptors for treating relapsed or refractory large B-cell lymphoma and mantle cell lymphoma.
  • Inflammatory and Liver Disease Pipeline: Clinical research and development programs focusing on targeted small molecules and biologics. Designed to address underserved indications including primary biliary cholangitis, ulcerative colitis, Crohn's disease, and advanced liver inflammation.

equipe executiva do Gilead Sciences

  • Daniel Patrick O'DayChairman & CEO
  • Andrew D. DickinsonExecutive VP & CFO
  • Johanna MercierChief Commercial & Corporate Affairs Officer
  • Dietmar P. BergerChief Medical Officer
  • Erin E. BurkhartSenior VP, Controller & Chief Accounting Officer
  • Jacquie RossSenior Vice President of Treasury & Investor Relations
  • Keeley M. Cain WettanExecutive VP, General Counsel of Legal & Compliance and Secretary
  • Jyoti K. MehraExecutive Vice President of Human Resources
  • Linda Slanec HigginsSenior Vice President of Research, Innovation & Portfolio
  • Flavius MartinExecutive Vice President of Research

Comunicados recentes

O que a Gilead Sciences (GILD) comunicou ao mercado, do mais recente para o mais antigo.

  1. 4 | GILEAD SCIENCES, INC.

Histórico de dividendos

Dividendos por ação pagos pela Gilead Sciences, por ano fiscal.

Dividendos por ação da Gilead Sciences por ano fiscal
Ano fiscalIntermediárioFinalEspecialTotal
FY2026(até o momento)———$3.2800
FY2025———$3.1600
FY2024———$3.0800
FY2023———$3.0000
FY2022———$2.9200

Principais indicadores financeiros

Resultados divulgados pela Gilead Sciences, em USD.

Cap. de mercado
208,5 bi
Receita (TTM)
31 bi
P/L
—
LPA (diluído, TTM)
-3.1
Dividend yield
1.9%
Margem de lucro
-12.5%
Receita e lucro anuais da Gilead Sciences
Fim do ano fiscalReceitaResultado operacionalLucro líquido
29,4 bi11,7 bi8,5 bi
28,8 bi1,7 bi480 mi
27,1 bi7,6 bi5,7 bi
27,3 bi7,3 bi4,6 bi